Pocenbrodib

CAS No. 2304372-79-8

Pocenbrodib( —— )

Catalog No. M36302 CAS No. 2304372-79-8

Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1587 In Stock
25MG 2594 In Stock
50MG 3143 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pocenbrodib
  • Note
    Research use only, not for human use.
  • Brief Description
    Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.
  • Description
    Pocenbrodib (compound II) is a CBP/p300 family of bromodomain inhibitor. Pocenbrodib has the potential for cancer research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2304372-79-8
  • Formula Weight
    525.57
  • Molecular Formula
    C28H32FN3O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](O)(C1=NC2=C(N1[C@H]3C[C@H](C(O)=O)CCC3)C=CC4=C2CC[C@H](C)N4C(OC)=O)C5=C(OC)C=CC(F)=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. George Luke. Inhibiting cyclic amp-responsive element-binding protein (creb). WO2020190780A1.
molnova catalog
related products
  • Menin-MLL inhibitor ...

    Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).

  • FLI-06

    FLI-06 is a Notch signaling inhibitor (EC50: 2.3 μM).

  • BRM/BRG1 ATP Inhibit...

    BRM/BRG1 ATP Inhibitor-2 is an inhibitor of BRG1/BRM ATPase and can be used in studies about the treatment of BAF-related disorders.